Randomized, Two-Cohort, Open-Label, Phase 3 Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint Inhibitor Therapy
This study is testing new combinations of immune-boosting drugs and chemotherapy for people with advanced lung cancer. It aims to help patients whose cancer has stopped responding to standard immunotherapy treatments.
You may be able to join if you are 18 or older, have advanced non-small cell lung cancer that stopped responding to previous treatments, and meet specific health guidelines. People with certain severe immune system diseases or active infections cannot participate.
Participants will be randomly placed into groups to receive either the experimental drug combination or standard chemotherapy alone. Your health will be closely monitored by the study team throughout the process.
The study is currently recruiting participants at multiple locations, including sites in Arkansas and California, United States.
- 1Tests new drug combinations for advanced lung cancer
- 2Designed for patients who need new options after standard treatments stopped working
- 3Currently active and recruiting participants at specific medical centers
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.